Quoin Pharmaceuticals, Ltd.

Quoin Pharmaceuticals is a specialty pharmaceutical company incorporated in Israel and headquartered in Ashburn, Virginia, operating as a subsidiary of Skinvisible, Inc. The company focuses on developing and commercializing therapeutic products for rare and orphan diseases, with a primary emphasis on dermatological conditions. Its lead candidate, QRX003, is a topical lotion formulation targeting Netherton Syndrome, a rare genetic skin disorder characterized by barrier dysfunction and inflammation.

The company's pipeline includes three additional product candidates in development: QRX004 for recessive dystrophic epidermolysis bullosa, QRX007 for Netherton Syndrome, and QRX008 for scleroderma. Quoin maintains research and licensing partnerships with Queensland University of Technology and Skinvisible Inc., along with consulting and service agreements with specialized research organizations to support its development activities.

Quoin operates with a minimal team of three full-time employees as of the most recent reporting period. The company was founded in 2018 and operates primarily within the United States market. As a late-stage specialty pharmaceutical company, Quoin's business model centers on advancing rare disease therapeutics toward commercialization, though specific revenue information is not publicly disclosed at this reporting level.